# NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

Study · id `cardio:ct-nct02305485` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02305485](<https://clinicaltrials.gov/study/NCT02305485>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02305485

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 560 participants.

## Technical summary

Registry record NCT02305485. Randomized; single masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 560 participants (planned count; ClinicalTrials.gov record NCT02305485, source copy `cardio:ctgov-nct02305485-2016-12-08`, retrieved 2026-10-26)
- Start date: 2014-11 (registry gives no type) (ClinicalTrials.gov record NCT02305485, source copy `cardio:ctgov-nct02305485-2016-12-08`, retrieved 2026-10-26)
- Primary completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02305485, source copy `cardio:ctgov-nct02305485-2016-12-08`, retrieved 2026-10-26)
- Completion: 2020-06 (anticipated) (ClinicalTrials.gov record NCT02305485, source copy `cardio:ctgov-nct02305485-2016-12-08`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02305485, source copy `cardio:ctgov-nct02305485-2016-12-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02305485-2016-12-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
- Condition: Coronary Artery Disease
- Intervention (Device): NeoVas BCS
- Intervention (Device): XIENCE PRIME EECSS
- Lead sponsor: Lepu Medical Technology (Beijing) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Lepu Medical Technology (Beijing) Co., Ltd. (`cardio:org-lepu-medical-technology-beijing-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents (`cardio:pubmed-29413240`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: 5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold: The NeoVas Randomized Trial (`cardio:pubmed-40930600`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 50e9ec61af2671760ae0c7fa41f9625453d95d4f732cfa898a2be2919a1045b2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
